相关实验视频

Updated: Jun 24, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

利拉格卢提德可以以PDH依赖的方式缓解实验性糖尿病心肌病

Jordan S F Chan^1,2,3, Amanda A Greenwell^1,2,3, Christina T Saed^1,2,3

¹Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.

The Journal of endocrinology

|June 11, 2024

概括

葡萄糖样-1受体 (GLP-1R) 激动剂利拉格胺通过增加葡萄糖氧化来改善糖尿病心肌病. 这种心脏保护作用需要pyruvate dehydrogenase (PDH) 活性,这表明PDH激活是新的治疗策略.

科学领域:

心血管研究研究心血管研究
代谢疾病代谢疾病
药理学药理学是指药理学的学科.

背景情况:

糖尿病心肌病 (DbCM) 是2型糖尿病 (T2D) 的并发症.
葡萄糖类-1受体 (GLP-1R) 激动剂,如利拉格卢提德,在治疗T2D和DbCM方面表现有前途.
心肌糖氧化的增加与liraglutide在实验T2D中的心脏保护作用有关.

研究的目的:

调查心肌糖氧化的增加是否对利拉格卢提德在T2D中的心脏保护作用至关重要.
为了确定在缺乏心肌细胞酸脱酶 (PDH) 的小鼠中,是否取消了利拉格卢提德的益处,这是葡萄糖氧化的关键酶.

主要方法:

使用了心肌细胞特异性pyruvate脱酶淘汰 (Pdha1CM-/-) 小鼠和对照 littermates (αMHCCre小鼠).
使用高脂肪饮食和链毒素诱导的实验T2D.
通过心声扫描进行了liraglutide或车载控制,并通过心声扫描评估心脏功能.

主要成果:

利拉格卢提德在两种基因型中都改善了葡萄糖平衡,但没有影响缩功能.
利拉格卢提德在对照小鼠中缓解了透缩功能障碍,但未能在Pdha1CM-/-小鼠中挽救这些缺陷.
心脏功能的改善取决于功能性PDH的存在.

结论:

增加心肌葡萄糖氧化对于GLP-1R激动剂在实验T2D中的心脏保护作用是必要的.
向酸盐脱酶活性可能为治疗糖尿病心肌病症提供一种新的治疗策略.

关键词:

糖尿病心肌病糖尿病心肌病腹痛功能障碍腹痛功能障碍腹痛功能障碍葡萄糖氧化过程中的葡萄糖.利拉格卢提德 (liraglutide) 是一种葡萄糖类药物.皮鲁酸盐脱酶的使用方法 2 型糖尿病 2 型糖尿病

更多相关视频

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...